Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R01CA201189-05S1
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$168,429Funder
National Institutes of Health (NIH)Principal Investigator
Nina BhardwajResearch Location
United States of AmericaLead Research Institution
Icahn School Of Medicine At Mount SinaiResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months whichoverall place cancer patients at a higher risk of severe illness and death if infected, although differences betweendistinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patientswho have recovered from COVID-19 may need to resume treatment, including immunotherapy for their diseaseeven though the repercussions of this infection on their immune systems are unknown. This project will determineif cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancerpatients who were not infected, and whether these phenotypes have an impact on the overall response rate andsurvival of this population.